Regeneron's Eylea boosts vision in patients with DME


Regeneron's (REGN +3.15%) Eylea treatment improved vision and maintained that improvement over two years in a Phase III trial of patients with diabetic macular edema (DME).

DME is a leading cause of blindness in younger and middle-aged adults; Eylea could potentially treat over 6M sufferers globally.

Regeneron and partner Bayer (BAYRY) are waiting for U.S. and EU approval of Eylea to treat DME; the therapy has already been authorized for other indications, including wet age-related macular edema. (PR)

From other sites
Comments (1)
  • toosmarttofail
    , contributor
    Comments (699) | Send Message
     
    ACTC's stemcell treatment makes Eylea an obsolete dinosaur.

     

    The only way REGN is a buy is if they use their cash to buy out ACTC before it's too late. ACTC's shareholders will probably not take less than 20x the current market cap for now.
    10 Feb 2014, 09:23 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs